Alyeska Investment Group, L.P. In8 Bio, Inc. Put Options Transaction History
Alyeska Investment Group, L.P.
- $16.5 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding INAB
# of Institutions
27Shares Held
7.46MCall Options Held
0Put Options Held
0-
Aigh Capital Management LLC Baltimore, MD1.67MShares$569,3760.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.42MShares$484,1240.0% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT1.12MShares$380,2100.0% of portfolio
-
Sigma Planning Corp Ann Arbor, MI851KShares$289,4350.01% of portfolio
-
683 Capital Management, LLC New York, NY591KShares$200,8750.05% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $8.33M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...